MET and non-small cell lung carcinoma: As an oral small-molecule tyrosine kinase inhibitor, Crizotinib, targeting the ALK, ROS1 and MET tyrosine kinases, is well approved to induce clinically significant responses in non-small cell lung cancer [20, 21].